Dr. Falk PharmaFalk Foundation
  • About us
    About us
    • Now into the future
    • Innovation drives everything
    • Why we are
    • Corporate Sustainability
    • Following the footsteps of our founder
    • Global presence & business partners
  • Indications
    Indications
    • Autoimmune Hepatitis
    • Chronic Constipation
    • Colonoscopy
    • Crohn’s Disease
    • Eosinophilic Esophagitis
    • Hemorrhoidal disease
    • Irritable Bowel Syndrome
    • Microscopic Colitis
    • Primary Biliary Cholangitis
    • Ulcerative colitis
  • Our Products
  • Partnering
  • Newsroom
Search
Please choose your country
  • Global (English)
  • Australia
  • België (Vlaams)
  • Belgique (Français)
  • Deutschland
  • España
  • France
  • Ireland
  • Italia
  • Luxembourg (Français)
  • Nederland
  • Österreich
  • Portugal
  • Россия
  • Schweiz (Deutsch)
  • Suisse (Français)
  • United Kingdom
more info

Contact:
Phone:+49 0761 1514 0 Fax:+49 0761 1514 321 Email: zentrale@drfalkpharma.de

  • Falk Foundation
  • Contact us
  • Events
  • Reporting adverse events
  • Falsified medicines regulations
  • Imprint
  • Data Privacy
  • Social media guidelines
  • About us
    • Now into the future
    • Innovation drives everything
    • Why we are
    • Corporate Sustainability
    • Following the footsteps of our founder
    • Global presence & business partners
  • Indications
    • Autoimmune Hepatitis
    • Chronic Constipation
    • Colonoscopy
    • Crohn’s Disease
    • Eosinophilic Esophagitis
    • Hemorrhoidal disease
    • Irritable Bowel Syndrome
    • Microscopic Colitis
    • Primary Biliary Cholangitis
    • Ulcerative colitis
  • Our Products
  • Partnering
  • Newsroom
  • Falk Foundation
  • Contact us
  • Events
  • Reporting adverse events
  • Falsified medicines regulations
  • Imprint
  • Data Privacy
  • Social media guidelines
Contact:
Phone:
+49 0761 1514 0
Fax:
+49 0761 1514 321
Email:
zentrale[at]drfalkpharma.de
  • Homepage
  • Search

Search results

113 results

  • NEWSROOM
    FDA clearance of IND application for naronapride
    ...to treat gastroparesis and subsequent expansion of ongoing phase 2b study to the US
  • Partnering UK
    Partnering UK Homepage Partnering Partnering UK Scientific Innovation We continuously strive for transforming ideas and current advances in medical treatment. As a partner, we offer comprehensive…
  • Indications
    Diseases and Treatments Homepage Indications The diseases we treat The following pages provide in-depth information about chronic diseases of the intestines, esophagus, liver, and bile ducts.…
  • NEWSROOM
    Initiation of Phase II Study of naronapride in patients with gastroparesis
    Renexxion Ireland and Dr. Falk Pharma announce that the first patient has been treated
  • NEWSROOM
    Collaboration and Licensing Agreement with Takeda and Zedira
    To Develop First-in-Class Celiac Disease Therapy
  • Detail
    Homepage Events 404 Homepage 404 Sorry, the page you requested was not found. Back to homepage Homepage Events
  • 404
    Homepage Events 404 Homepage 404 Sorry, the page you requested was not found. Back to homepage Homepage Events 404 Homepage 404 Sorry, the page you requested was not found. Back to homepage
  • «
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • »
Falk Foundation

Discover the range of continuing education opportunities for physicians and pharmacists provided by the Falk Foundation e.V.

Dr. Falk Pharma GmbH

Dr. Falk Pharma is the expert in digestive and metabolic medicine. As a research-based family business with global presence, we focus on the development and distribution of innovative medicines that improve patients’ health and well-being. 

  • Falk Foundation
  • Events
  • Headquarters
  • Reporting adverse events
  • Falsified medicines regulations
  • Social media guidelines
© 2026 Dr. Falk Pharma GmbH
  • Imprint
  • Data Privacy
Notice

This website is an international information resource intended for healthcare professionals outside the United States (US) and United Kingdom (UK).

I am a health care professional outside the US and UK.

Accept
Notice
I confirm I am a UK or Irish resident and have been prescribed either Budenofalk®, Jorveza®, Salofalk® or Ursofalk®
Accept

You are leaving the website of Dr. Falk Pharma.

We are not liable for the accuracy of any content published on third party websites - such as the one you are about to be forwarded to.